FCRL2 expression was significantly elevated on CLL samples with mutated (M-CLL) as compared to unmutated (U-CLL) IGHV sequences, showed 94.4% concordance with IGHV mutation status, and was superior to nine other factors (including IGHV status) analyzed in predicting time to first treatment (TFT). The gene discussed is FCRL2; the disease is B-cell chronic lymphocytic leukemia.